Unlocking antibiotic-free acne control with Benzalkonium Chloride
Are you developing modern acne treatments that deliver strong antimicrobial performance—without relying on antibiotics? Looking for an active that can help overcome antibiotic resistance and biofilm-related treatment failure, while still supporting daily-use skin tolerability? Then Benzalkonium Chloride (BKC) may be the solution you’ve been overlooking.
In this application note, we explore how low concentrations of pharmacopeial-grade Benzalkonium Chloride can provide rapid, broad-spectrum microbial reduction against acne-associated organisms, while maintaining a favorable tolerability profile in semisolid formulations. The study combines formulation development with analytical confirmation and antimicrobial testing to deliver practical, formulation-ready insights for next-generation topical acne care.
BKC as a modern active for topical acne formulations
This application study evaluated BKC in hydroxyethyl cellulose (HEC) gel formulations at low concentrations (0.03%, 0.06%, and 0.13%), designed to target key acne-related microorganisms including Cutibacterium acnes, S. aureus, MRSA, and S. epidermidis. The results showed rapid antimicrobial efficacy (≥ 4.5–5 log₁₀ reduction within 2 hours) even at the lowest concentration, supporting BKC as a strong candidate for antibiotic-free acne product design.
To ensure formulation robustness, BKC content and stability were confirmed using a modified USP HPLC method, verifying label potency and chemical stability over time. Finally, dermal tolerability was assessed in an ISO-standard irritation study, where low BKC concentrations demonstrated good skin compatibility comparable to a benzoyl peroxide control—highlighting BKC’s suitability for daily topical use.
Download the application note
Join us to refine your research and laboratory proficiency with the actionable knowledge provided in our technical paper. Download our application note by filling the form below.
